Some Reflections on IBM Watson and on Women’s Health

[...]our plan for the Watson paper has also gone awry; it will now appear in a subsequent issue. The Boston Globe's newly launched Statnews.com reported that many pharmaceutical companies and academic research institutions fail to report clinical data and results to one very important repositor...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2016, Vol.38 (1), p.1-2
Main Author: Shader, Richard I., MD
Format: Article
Language:English
Subjects:
Datasets
Drug therapy
Internal Medicine
Medical Education
Miscarriage
Reporting requirements
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]our plan for the Watson paper has also gone awry; it will now appear in a subsequent issue. The Boston Globe's newly launched Statnews.com reported that many pharmaceutical companies and academic research institutions fail to report clinical data and results to one very important repository, ClinicalTrials.gov.8 To make matters even worse, neither the NIH nor the FDA has enforced mandatory reporting since it became law in 2008 for studies conducted with public funds.9 Thus the ClinicalTrials.gov database may not capture a complete data set of the efficacy or safety of the available treatments for a disease.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.12.008